PDCD1 and neoplasm: ICIs are monoclonal antibodies that target PD-1/programmed death ligand 1 (PD-L1) or CTLA-4, reactivating the anti-tumor immune response that is inhibited by the overexpression of these proteins by tumor cells (1).